Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...